Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044382 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00044382 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 25 participants.
The verdict
NCT00044382, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .
Interventions
- DRUG CC-5013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2002-02-01 |
| Est. Completion | 2007-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044382
The ClinicalTrials.gov registry entry for NCT00044382 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-5013 is the first listed.
NCT00044382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044382 about?
NCT00044382 is a clinical study titled "Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome". To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .
What is the current status of trial NCT00044382?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2002-02-01. Estimated completion is 2007-01-30.
What interventions are being tested in trial NCT00044382?
The interventions under investigation include: CC-5013 (DRUG).
Who is sponsoring clinical trial NCT00044382?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.